CareDx, Inc. (CDNA) saw its shares increase by 35.6%, closing at $40.34 following the announcement of the finalized Medicare Local Coverage Determination for molecular testing related to solid organ allograft rejection. This decision solidifies coverage for CareDx’s transplant surveillance offerings in kidney, heart, and lung, reflecting a marked investor optimism.
For the upcoming quarterly earnings report, CareDx is expected to report earnings of $0.22 per share, a 120% increase year-over-year, with projected revenues of $114.35 million, marking a 31.9% rise from the previous year. The consensus EPS estimate has remained stable over the last 30 days.
In related news, HCA Healthcare, Inc. (HCA) closed at $385.74, up 1.8%, with a consensus EPS estimate for the next report at $7.38, reflecting a 7.9% year-over-year change. HCA’s stock carries a Zacks Rank of #4 (Sell), while CareDx holds a Zacks Rank of #3 (Hold).
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
